Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Denosumab made available on NHS

  • Comment

Women who have an increased risk of osteoporotic fractures will be able to get a new treatment on the NHS.

The NICE issued its final recommendation on denosumab, saying it was “good news” for post menopausal women in osteoporosis.

The treatment is given as an injection and mimics the body’s system of controlling the breakdown of bones.

Marketed under the trade name Prolia, denosumab targets cells that break down bones. This in turn increases bone density and reduces the risk of fracture.

Dr Carole Longson, health technology evaluation centre director at NICE, said: “We are pleased to be able to recommend denosumab to help prevent osteoporotic fractures in post-menopausal women at increased risk of fracture who are unable to take oral bisphosphonates.

“Denosumab joins the range of treatments that NICE has already advised should be available on the NHS, to help stop a fracture from occurring in the first place, or to help women who have previously had a fracture.

“This new guidance is good news for post-menopausal women at increased risk of fracture as it means that they now have a further treatment option to help them avoid suffering an osteoporotic fracture.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs